Back

Morpho-molecular features of Epithelial Mesenchymal Transition associate with clinical outcome in patients with rectal cancer

Gwerder, M.; Demir, C. S.; Williams, H. L.; Lugli, A.; Martinez, C. G.; Kowal, j.; Khan, A.; Kirchner, P.; Koessler, T.; Berger, M. D.; Weigert, M.; Zlobec, I.

2024-11-10 cancer biology
10.1101/2024.11.07.622481 bioRxiv
Show abstract

In rectal cancer, where part of the patients undergoes chemoradiotherapy, there is a need for improved pretreatment biomarkers applicable to biopsies. Tumor budding (TB) is a biomarker used in colon cancer, and due to its link to epithelial-mesenchymal transition (EMT), is hypothesized to be a potential marker for therapy resistance. Assessment of the utility of tumor buds in rectal biopsies is challenging due to their rarity. As EMT-related processes are also seen in other morphological features beyond tumor buds, we investigated EMT in tumor tissue including morphological features such as tumor cluster size and fibril-like structures. To do so, we leveraged a cohort of colon cancer whole-slide images and another cohort consisting of rectal cancer biopsies, visualized using hyperplex immunofluorescence to identify tumor and EMT-associated proteins. We built a custom image analysis pipeline to detect and segment tumor buds and other morphological features and correlated them with molecular expression intensities. We found strong correlations of EMT up-regulation and morphological transition states, both at the invasive margin and the tumor center. We furthermore observed a link between morpho-molecular transitions and histological growth patterns, which in turn can inform novel biomarkers. Finally, quantification of these morpho-molecular transition states in rectal biopsies showed their impact on survival after neoadjuvant chemoradiotherapy.

Matching journals

The top 3 journals account for 50% of the predicted probability mass.

1
Cancers
200 papers in training set
Top 0.1%
22.9%
2
Scientific Reports
3102 papers in training set
Top 2%
14.9%
3
npj Precision Oncology
48 papers in training set
Top 0.1%
14.6%
50% of probability mass above
4
British Journal of Cancer
42 papers in training set
Top 0.3%
4.4%
5
Nature Communications
4913 papers in training set
Top 43%
2.8%
6
PLOS ONE
4510 papers in training set
Top 45%
2.6%
7
Frontiers in Oncology
95 papers in training set
Top 2%
2.4%
8
eLife
5422 papers in training set
Top 35%
2.1%
9
Cancer Research
116 papers in training set
Top 1%
2.1%
10
Journal of Clinical Medicine
91 papers in training set
Top 3%
1.7%
11
BMC Cancer
52 papers in training set
Top 1%
1.7%
12
Clinical Cancer Research
58 papers in training set
Top 1.0%
1.7%
13
Neoplasia
22 papers in training set
Top 0.2%
1.7%
14
International Journal of Cancer
42 papers in training set
Top 0.8%
1.4%
15
Molecular Oncology
50 papers in training set
Top 0.6%
1.2%
16
The Journal of Pathology
22 papers in training set
Top 0.2%
1.2%
17
Journal of Translational Medicine
46 papers in training set
Top 2%
1.0%
18
iScience
1063 papers in training set
Top 24%
1.0%
19
Translational Oncology
18 papers in training set
Top 0.3%
0.8%
20
PLOS Computational Biology
1633 papers in training set
Top 23%
0.8%
21
Oncogene
76 papers in training set
Top 2%
0.8%
22
Frontiers in Bioinformatics
45 papers in training set
Top 1%
0.7%
23
The Lancet Digital Health
25 papers in training set
Top 1%
0.7%
24
Cell Reports Medicine
140 papers in training set
Top 9%
0.7%
25
Computational and Structural Biotechnology Journal
216 papers in training set
Top 12%
0.5%
26
Frontiers in Molecular Biosciences
100 papers in training set
Top 7%
0.5%
27
PeerJ
261 papers in training set
Top 19%
0.5%
28
Cancer Research Communications
46 papers in training set
Top 2%
0.5%